This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Nonalcoholic Fatty Liver Disease (NAFLD)

Anti-LPS Antibody Treatment for Pediatric NAFLD

Sponsored by Miriam Vos, MD

About this trial

Last updated 4 years ago

Study ID

IRB00084686

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

Yes

Accepting

18-75 Years
6 to 19 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 6 years ago

What is this trial about?

The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver as measured by alanine transaminase (ALT). Specifically, investigators will measure percent change in ALT from Week 0 to Week 12 in treatment compared to placebo.

What are the participation requirements?

Yes

Inclusion Criteria

- Nonalcoholic fatty liver disease (NAFLD) diagnosis confirmed by liver biopsy or MRI

- ALT ≥ 2 x ULN at screening (girls ≥ 46, boys ≥ 54)

- Written informed parent consent and child assent

- Willingness to take IMM-124E or placebo powder 3 x daily for 12 weeks

- At least 2 months of attempted lifestyle changes after diagnosis

No

Exclusion Criteria

- Disease or condition deemed by physician to interfere with absorption, digestion, or mechanism of intervention of drug

- Diagnosis of diabetes and an HbA1c of > 9%

- Change in supplement or anti-oxidant therapy within past 90 days (must be on a stable dose and willing to continue it throughout the trial or not on any vitamin or supplement, includes SAMe, vitamin E, betaine, Milk thistle etc)

- Use of probiotics or antibiotics in the past 30 days

- Use of anti-NAFLD medications (metformin, thiazolidinediones, UDCA) in the 30 days prior to randomization

- Acute illness within past 2 weeks prior to enrollment (defined as fever > 100.4ºF)

- Planned pregnancy, nursing an infant, confirmed or suspected to be pregnant between screening and time of study enrollment

- Evidence of other chronic liver disease other than NAFLD (Hepatitis B and C, Alpha-1 antitrypsin, Wilson's disease)

- Intolerance to lactose or dairy-based products

- Unable to have blood drawn at study visits

- Unwillingness to provide and/or collect stool samples

- Current gastrointestinal (GI) bleeding or inflammatory bowel disease (irritable bowel disease (IBD), colitis)

- Current enrollment in another therapeutic clinical trial or receipt of an investigational study drug within 6 months prior to study enrollment

- Participants who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator

Locations

Location

Status